Acadia Pharmaceuticals buy UBS Group AG
Start price
17.10.23
/
50%
€21.80
Target price
17.10.24
€31.28
Performance (%)
-25.67%
Price
19.07.24
€16.31
Summary
This prediction is currently active. The prediction for Acadia Pharmaceuticals disappoints with a performance of -25.67%. This prediction currently runs until 17.10.24. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Acadia Pharmaceuticals | 0.123% | 0.123% |
iShares Core DAX® | -0.543% | 1.491% |
iShares Nasdaq 100 | -2.696% | -1.235% |
iShares Nikkei 225® | -2.863% | 2.491% |
iShares S&P 500 | -1.105% | 0.013% |
Comments by UBS_Group_AG for this prediction
In the thread Acadia Pharmaceuticals diskutieren
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $33.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat